About Castle Biosciences
Castle Biosciences is a publicly listed company based in Friendswood (United States) founded in 2008. Diagnostic tests for cancer prognosis are provided. Castle Biosciences has raised $61.97 million across 17 funding rounds from investors including SVB, BrightEdge and Industry Ventures. The company has 761 employees. Castle Biosciences has completed 3 acquisitions, including AltheaDx, Castle Biosciences and Previse. Its website castlebiosciences.com draws about 27 thousand monthly visits. Castle Biosciences offers products and services including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is CASTLE BIOSCIENCES INC. Its competitors include Denali Therapeutics, Poseida Therapeutics and Juno Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Castle Biosciences was founded in 2008 and is headquartered in Friendswood, United States. Operations focus on the biotechnology sector, where prognostic assays for conditions such as uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme are developed. Additional tools like DecisionDx DiffDx-Melanoma for diagnosing melanocytic lesions are offered to support clinical decisions in oncology.
- Annual Revenue$344.23 M (USD)3.66as on Dec 31, 2025
- Net Profit-$24.16 M (USD)-232.41as on Dec 31, 2025
- EBITDA-$2.04 M (USD)-108.27as on Dec 31, 2025
- Total Equity Funding$61.97M (USD)
in 17 rounds
- Latest Funding Round$10M (USD), Post-IPO
Jul 2019
- InvestorsSVB
& 4 more
- Employee Count761
- Investments & AcquisitionsAltheaDx
& 2 more
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix.
Assesses risk of melanoma metastasis for treatment guidance.
Evaluates metastasis risk in squamous cell carcinoma patients.
Predicts progression risk for Barrett's esophagus to cancer.
Guides mental health medication based on genetic profiles.
Apps and channels of Castle Biosciences
its YouTube channel Castle Biosciences has 578 subscribers and 30 videos.
Videos from Castle Biosciences
The most watched videos on Castle Biosciences's YouTube channel, Castle Biosciences (578 subscribers). Click a video to play it here.
More on Castle Biosciences.
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $61.97M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.97M
- Total Rounds 17
- Last Round Post-IPO — $10M
- First Round $935,899
(Mar 2009)
- Investors Count 5
Latest 10 of 17 funding rounds of Castle Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $10M | Post-IPO | – | – | – |
| Mar 2019 | $12M | Series F | – | BrightEdge | – |
| May 2018 | $5.06M | Series F | – | – | – |
| Jan 2018 | $5.48M | Series F | – | – | – |
| Jun 2017 | $6M | Debt – Conventional | – | – | |
| Mar 2016 | $14M | Debt – Conventional | – | – | |
| Jul 2015 | $11.7M | Series F | – | Industry Ventures | |
| Aug 2014 | $11.8M | Series D | – | Health Quest Capital | |
| Aug 2014 | $7.52M | Series C | – | – | – |
| Aug 2014 | $1.5M | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Castle Biosciences
Castle Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, BrightEdge and Industry Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
BrightEdge is focused on impact investment in cancer care innovation. | brightedgefund.org | |||
Investments in private tech ecosystem are made by Industry Ventures. | industryventures.com | San Francisco, United States | ||
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Venture capital is directed toward life sciences and technology sectors. | mtngp.com | Nashville, United States | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Castle Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Castle Biosciences
40 people are tracked at Castle Biosciences (24 in leadership, 7 in board & advisors, 9 in team); the tracked headcount is 761.
| Name | Role | Group |
|---|---|---|
Toby Juvenal | Chief Commercial Officer | Leadership |
Kristen Oelschlager | COO | Leadership |
Noreen Manning | VP, Reimbursement | Leadership |
John Abbott | VP, Finance | Leadership |
Kevin Doman | VP, Sales | Leadership |
Keli Greenberg | VP, Human Resources | Leadership |
Trisha Poteet | VP, Clinical Services | Leadership |
Sherri Borman | Executive Laboratory Director | Leadership |
Jay Braxton | VP, Medical Affairs | Leadership |
Chris Otte | VP, Information Technology | Leadership |
Camilla Zuckero | VP, Investor Relations & Corporate Affairs | Leadership |
Lj Delponte | Sales Director GI East | Leadership |
Ian Fladoos | Vice President Of Sales | Leadership |
Sameer Abdullah | Associate Director, Financial Planning & Analysis | Leadership |
Joshua Albers | Director, Software And Application Development | Leadership |
Matthew Goldberg | Senior Vice President, Medical | Leadership |
Derek Maetzold | Founder, President & CEO | Leadership |
Michael Maltby | Executive Director, Managed Care | Leadership |
Frank Stokes | CFO | Leadership |
Jason March | Product Director | Leadership |
20 more people are available in the full profile.
Complete people profiles for Castle Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Castle Biosciences
Castle Biosciences is a publicly listed company on the NASDAQ with ticker symbol CSTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jul 2019
- Listed onNASDAQ: CSTL
- Listed entityCastle Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS14843C1053
- Share price$32.88 (+0.37% on the day) · 2026-10-13
- Market capitalisation$1.00B
- EPS (diluted, trailing year)$-0.65
- Volume (last session)241,698
Financials of Castle Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $344.2M | -$24.2M | -$2.0M |
| 2024 | $332.1M | $18.2M | $24.7M |
| 2023 | $219.8M | -$57.5M | -$55.6M |
| 2022 | $137.0M | -$67.1M | -$80.6M |
| 2021 | $94.1M | -$31.3M | -$36.7M |
Detailed financial statements for Castle Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Castle Biosciences
Castle Biosciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AltheaDx, Castle Biosciences and Previse.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cancer detection and prevention solutions are developed by Previse. | previsedx.com | Baltimore, United States | 2018 | May 2025 | •••• | |
Molecular diagnostics and biomarker discovery services are offered. | altheadx.com | San Diego, United States | 2009 | Apr 2022 | $65M | |
Precision diagnostic and prognostic tests are developed by Castle Biosciences. | cernostics.com | Pittsburgh, United States | 2008 | Oct 2021 | $30M |
Complete acquisition details for Castle Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Castle Biosciences
7 dated milestones of Castle Biosciences across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Castle Biosciences is founded.
- Funding First funding round of $936K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
- Acquisition Acquires Castle Biosciences.
- Acquisition Acquires AltheaDx.
- Acquisition Acquires Previse.
Competitors of Castle Biosciences
Castle Biosciences has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Juno Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. |
Detailed competitors of Castle Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Castle Biosciences
The website of Castle Biosciences (castlebiosciences.com) receives about 26.9K visits a month.
- Monthly visits26.9K
▼ 14% vs previous month
Websites whose visitors overlap most with Castle Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aruplab.com | 100% | 138.9K | #300,732 | View details | |
| tempus.com | 100% | 150.9K | #320,246 | View details | |
| webmd.com | 86% | 34.4M | #1,980 | View details | |
| oneome.com | 82% | 4.1K | #4,245,937 | View details | |
mayoclinic.com | mayoclinic.com | 81% | #171,894 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Castle Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Castle Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Castle Biosciences
Complete news archive for Castle Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Biosciences
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Castle Biosciences is headquartered in Friendswood, United States. It is registered at Friendswood, Texas, United States.
Castle Biosciences is a funded company, having raised a total of $61.97M across 17 funding rounds to date. The company's 1st funding round was a Series B of $1.5M, raised on Mar 2009.
Castle Biosciences has 761 employees.
Annual revenue of Castle Biosciences is $344.23M as on Dec 31, 2025.
Castle Biosciences was founded in 2008 and is headquartered in Friendswood, United States. Operations focus on the biotechnology sector, where prognostic assays for conditions such as uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme are developed. Additional tools like DecisionDx DiffDx-Melanoma for diagnosing melanocytic lesions are offered to support clinical decisions in oncology.
Castle Biosciences's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Castle Biosciences offers DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix.
Yes, Castle Biosciences is publicly traded on NASDAQ under the ticker symbol CSTL.
Castle Biosciences has made 3 acquisitions, including AltheaDx, Castle Biosciences, and Previse.
Castle Biosciences has 5 investors. Key investors include SVB, BrightEdge, Industry Ventures, Health Quest Capital, and Mountain Group Partners.
Castle Biosciences operates through Castle Biosciences Inc.